Summary
Thiazolidinediones, such as rosiglitazone, have been shown to increase insulin sensitivity and reduce other cardiovascular risk factors but increase fluid retention and the risk of heart failure. This article discusses results of the Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients with Cardiovascular History [APPROACH; NCT00116831] trial.
- diabetes mellitus
- lipid disorders
- prevention & screening clinical trials
- prevention & screening
- © 2009 MD Conference Express